Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Hansen's disease


Other Names for this Disease

  • Leprosy
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Treatment

Clinical Trials & Research for this Disease

  • ClinicalTrials.gov lists trials that are studying or have studied Hansen's disease. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.
  • The National Institute of Arthritis and Infectious Diseases (NIAID) supports the Leprosy Research Support program, which includes a repository to provide standardized, quality controlled Mycobacterium leprae research reagents as well as the maintenance of an armadillo colony for the propagation of leprosy bacilli. Click on the link to learn more about the program. 

Medical Products

The medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.


Generic Name Clofazimine
Trade Name
(Manufacturer Name)
Lamprene®
(Novartis Pharmaceutical Corporation)
Indication
The FDA has approved this product to be used in this manner.
Treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.
More Information about this product Drug Information Portal

Generic Name Thalidomide
Trade Name
(Manufacturer Name)
Thalomid®
(Celgene Corporation)
Indication
The FDA has approved this product to be used in this manner.
Acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) and as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrences.
More Information about this product Drug Information Portal
Medline Plus Health Information

Other Names for this Disease
  • Leprosy
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.